Answers are grounded in this paper and cite their sources.
Graves' disease (GD) is an autoimmune thyroid disorder characterized by thyrotropin receptor antibodies (TRAb) and is the leading cause of hyperthyroidism in iodine-sufficient regions. Graves' orbitopathy (GO), the most common extrathyroidal manifestation of Graves’ disease, is characterized by immune-mediated inflammation and remodeling of the orbital tissues and imposes a substantial functional and psychosocial burden. Selenium, an essential trace element with selenoprotein-mediated antioxidant, anti-inflammatory, and immunomodulatory functions, has attracted considerable interest as an adjunctive treatment for both conditions. Based on our analysis of clinical trials and observational studies, the current evidence does not support routine selenium supplementation in Graves’ hyperthyroidism. In GO, the benefit of selenium is most consistently supported in mild, active disease. Whether baseline or post-treatment selenium levels affect its efficacy and safety remains unclear, as baseline status may be confounded by disease severity. Randomized controlled trials (RCTs) stratified by selenium status, with mechanistically relevant secondary endpoints, are required before recommendations can be extended to specific populations. This review analyzed 20 core clinical studies published between 2002 and 2026: 12 controlled intervention studies, comprising six studies in Graves’ disease and six studies in Graves’ orbitopathy, and eight observational studies or meta-analyses. Additional mechanistic, preclinical, functional-food, guideline, safety, and methodological references were used to provide context, totaling 52 references including the core studies. The literature was identified through PubMed, Scopus, and the Functional Food Center/Food Science Publisher database. Novelty: This review integrates twenty studies (six controlled GD trials, six controlled GO trials, and eight observational studies or meta-analyses), several of which were unavailable to previous reviews, including the 2026 GRASS, 2025 SeGOSS, and 2025 Philippine RCTs. It provides an up-to-date, balanced assessment of the supporting and conflicting evidence for each proposed response modifier. Specific emphasis is placed on selenium status as a potential modifier of treatment efficacy, distinguishing directly measured selenium concentrations from geographic assumptions about baseline selenium sufficiency. This review also considers the biokinetic hypothesis that selenium absorption is impaired during acute hyperthyroidism and highlights it as an underappreciated variable in trial design and interpretation.
No takes yet. Share an insight, caveat, or question.
Martirosyan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: